Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $312,150.00 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction on Monday, June 15th. The stock was sold at an average price of $20.81, for a total transaction of $312,150.00. Following the completion of the transaction, the insider directly owned 395,467 shares of the company’s stock, valued at $8,229,668.27. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Brian Daniel Webster also recently made the following trade(s):

• On Friday, May 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.96, for a total transaction of $314,400.00.
• On Wednesday, April 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.04, for a total transaction of $300,600.00.

Kestra Medical Technologies Stock Performance

KMTS opened at $19.93 on Friday. Kestra Medical Technologies, Ltd. has a 12 month low of $13.25 and a 12 month high of $30.00. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.15. The stock has a 50-day moving average of $20.71 and a 200 day moving average of $22.85. The firm has a market cap of $1.16 billion, a P/E ratio of -5.03 and a beta of 0.83.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.01). The company had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. Kestra Medical Technologies’s revenue for the quarter was up 62.7% compared to the same quarter last year. As a group, research analysts forecast that Kestra Medical Technologies, Ltd. will post -2.34 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on KMTS. The Goldman Sachs Group lowered their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. BTIG Research reissued a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a research note on Tuesday, April 7th. Finally, Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Kestra Medical Technologies currently has an average rating of “Hold” and a consensus price target of $27.40.

Institutional Investors Weigh In On Kestra Medical Technologies

Institutional investors and hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD boosted its holdings in Kestra Medical Technologies by 137.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock valued at $115,878,000 after acquiring an additional 2,529,851 shares during the period. Franklin Resources Inc. increased its stake in Kestra Medical Technologies by 180.8% in the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock worth $25,221,000 after purchasing an additional 612,343 shares during the period. Millennium Management LLC bought a new stake in shares of Kestra Medical Technologies during the first quarter worth $11,036,000. Brown Advisory Inc. lifted its position in shares of Kestra Medical Technologies by 34.1% during the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock worth $44,775,000 after purchasing an additional 428,996 shares during the last quarter. Finally, Summit Partners Public Asset Management LLC purchased a new stake in shares of Kestra Medical Technologies during the fourth quarter valued at $9,282,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.